

Pancreatic Adenocarcinoma Cancer Pathways

Patient Name: _____ **Date of Birth:** _____

Member ID: _____ **Treatment Start Date:** _____

Stage: _____ **Pathology:** _____

ECOG Status: 1 2 3 4 **ICD-10 Code:** _____

Line of Therapy:

- Neoadjuvant/Pre-op
 Adjuvant/Post Op
 1st Line
 2nd Line
 3rd Line
 3rd Line+
 Maintenance

Biomarkers/Attributes: (select all that apply)

BRCA 1/2: <input type="checkbox"/> Negative <input type="checkbox"/> Positive <input type="checkbox"/> Not Reported	Microsatellite instability: <input type="checkbox"/> dMMR/MSI-H <input type="checkbox"/> MSI-L <input type="checkbox"/> Not Reported
PALB2: <input type="checkbox"/> Negative <input type="checkbox"/> Positive <input type="checkbox"/> Not Reported	NTRK Fusion: <input type="checkbox"/> Absent <input type="checkbox"/> Present <input type="checkbox"/> Not Reported

Neoadjuvant (Resectable/Borderline Resectable)

- Fluorouracil/Leucovorin + Oxaliplatin + Irinotecan (FOLFIRINOX/mFOLFIRINOX)
- Gemcitabine + Albumin-bound Paclitaxel (G-nP)
- FOLFIRINOX/mFOLFIRINOX (BRCA1/2 or PALB2)

Adjuvant (Resectable)

- Fluorouracil/Leucovorin + Oxaliplatin + Irinotecan (mFOLFIRINOX)
- Gemcitabine + Capecitabine
- Gemcitabine
- Fluorouracil IVP/leucovorin

Locally Advanced/Metastatic | First Line of Therapy

- Fluorouracil/Leucovorin + Oxaliplatin + Irinotecan (FOLFIRINOX/ mFOLFIRINOX)
- FOLFIRINOX/ mFOLFIRINOX (BRCA1/2 or PALB2)
- Gemcitabine + Albumin-bound Paclitaxel (G-nP)
- Gemcitabine
- Gemcitabine + Erlotinib

Metastatic Second and Subsequent Lines of Therapy

- Fluorouracil/Leucovorin + Liposomal Irinotecan
- Fluorouracil/Leucovorin + Irinotecan (FOLFIRI)
- Modified Fluorouracil/Leucovorin + Oxaliplatin + Irinotecan (mFOLFIRINOX)
- Gemcitabine + Albumin-bound Paclitaxel (G-nP)
- Gemcitabine

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Last Review [2.22.2022] | Effective [3.1.2022]/ slf



References:

Abrams MJ, Huber KE, Knisely JP, Chang BW, Russo SM, Saif MW. Capecitabine as a Radiosensitizer in Adjuvant Chemoradiotherapy for Pancreatic Cancer: A Retrospective Study. *Anticancer Res.* 2015;35(12):6901-6907.

Ahn DH, Krishna K, Blazer M, et al. A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis. *Ther Adv Med Oncol.* 2017;9(2):75-82. doi:10.1177/1758834016676011

Burris H, Moore M, Anderson J, et al. Improvements in Survival and Clinical Benefit with Gemcitabine as First-Line Therapy for Patients with Advanced Pancreas Cancer: A Randomized Trial. *J Clin Oncol.* 15:2403-13.

Cartwright TH, Cohn A, Varkey JA, et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. *J Clin Oncol.* 2002;20(1):160-164. doi:10.1200/JCO.2002.20.1.160

Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med.* 2011;364(19):1817-1825. doi:10.1056/NEJMoa1011923

Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. *N Engl J Med.* 2018;379(25):2395-2406. doi:10.1056/NEJMoa1809775

Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. *J Clin Oncol.* 2009 Nov 20;27(33):5513-8. doi: 10.1200/JCO.2009.24.2446. Epub 2009 Oct 26. PMID: 19858379.

DOI: 10.1200/JCO.2018.36.4_suppl.204 *Journal of Clinical Oncology* 36, no. 4_suppl (February 01, 2018) 204-204.

Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. *N Engl J Med.* 2018;378(8):731-739. doi:10.1056/NEJMoa1714448

Drilon A, Siena S, Ou SI, et al. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). *Cancer Discov.* 2017;7(4):400-409. doi:10.1158/2159-8290.CD-16-1237

Ducreux M, Mitry E, Ould-Kaci M, et al. Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. *Ann Oncol.* 2004;15(3):467-473. doi:10.1093/annonc/mdh098

ESPAC-5F: DOI: 10.1200/JCO.2020.38.15_suppl.4505 *Journal of Clinical Oncology* 38, no. 15_suppl (May 20, 2020) 4505-4505. Published online May 25, 2020

Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. *J Clin Oncol.* 2008;26(21):3496-3502. doi:10.1200/JCO.2007.15.8634

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Gill S, Ko YJ, Cripps C, et al. PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy. *J Clin Oncol*. 2016;34(32):3914-3920. doi:10.1200/JCO.2016.68.5776

Golan T, Barenboim A, Lahat G, et al. Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer. *Ann Surg Oncol*. 2020;27(10):3963-3970. doi:10.1245/s10434-020-08469-8

Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. *N Engl J Med*. 2019;381(4):317-327. doi:10.1056/NEJMoa1903387

Habermehl D, Kessel K, Welzel T, et al. Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. *Radiat Oncol*. 2012;7:28. Published 2012 Mar 2. doi:10.1186/1748-717X-7-28

Hammel P, Huguet F, van Laethem JL, et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. *JAMA*. 2016;315(17):1844-1853. doi:10.1001/jama.2016.4324

Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. *J Clin Oncol*. 2006;24(24):3946-3952. doi:10.1200/JCO.2005.05.1490

Hurt CN, Falk S, Crosby T, et al. Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer. *Br J Cancer*. 2017;116(10):1264-1270. doi:10.1038/bjc.2017.95

Janssen QP, Buettner S, Suker M, et al. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. *J Natl Cancer Inst*. 2019;111(8):782-794. doi:10.1093/jnci/djz073

Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. *J Clin Oncol*. 2015;33(3):244-250. doi:10.1200/JCO.2014.56.2728

Kim HS, Yi SY, Jun HJ, et al. Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer. *Anticancer Drugs*. 2010;21(1):107-112. doi:10.1097/CAD.0b013e328332a7fc

Krishnan S, Rana V, Janjan NA, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. *Cancer*. 2007;110(1):47-55. doi:10.1002/cncr.22735

Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science*. 2017;357(6349):409-413. doi:10.1126/science.aan6733

Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *N Engl J Med*. 2015;372(26):2509-2520. doi:10.1056/NEJMoa1500596

Loehrer PJ Sr, Feng Y, Cardenas H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. *J Clin Oncol*. 2011;29(31):4105-4112. doi:10.1200/JCO.2011.34.8904

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. *J Clin Oncol*. 2020;38(1):1-10. doi:10.1200/JCO.19.02105

Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. *Lancet*. 2020;395(10242):2008-2020. doi:10.1016/S0140-6736(20)30974-0

Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W; National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol*. 2007 May 20;25(15):1960-6. doi: 10.1200/JCO.2006.07.9525. Epub 2007 Apr 23. PMID: 17452677.

Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicenter, randomized, phase 2 trial. *Lancet Oncol*. 2013;14(4):317-326. doi:10.1016/S1470-2045(13)70021-4

Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicenter, randomized, phase 2 trial. *Lancet Oncol*. 2013;14(4):317-326. doi:10.1016/S1470-2045(13)70021-4

Neoptolemos JP, Kerr DJ, Beger H, et al. ESPAC-1 trial progress report: the European randomized adjuvant study comparing radiochemotherapy, 6 months chemotherapy and combination therapy versus observation in pancreatic cancer. *Digestion*. 1997;58(6):570-577. doi:10.1159/000201503

Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. *Lancet*. 2017;389(10073):1011-1024. doi:10.1016/S0140-6736(16)32409-6

Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. *JAMA*. 2010;304(10):1073-1081. doi:10.1001/jama.2010.1275

Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. *JAMA*. 2010;304(10):1073-1081. doi:10.1001/jama.2010.1275

Neuzillet C, Hentic O, Rousseau B, et al. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. *World J Gastroenterol*. 2012;18(33):4533-4541. doi:10.3748/wjg.v18.i33.4533

Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. *JAMA*. 2007;297(3):267-277. doi:10.1001/jama.297.3.267

Oettle H, Riess H, Stieler JM, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. *J Clin Oncol*. 2014;32(23):2423-2429. doi:10.1200/JCO.2013.53.6995

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. *Eur J Cancer*. 2011;47(11):1676-1681. doi:10.1016/j.ejca.2011.04.011

Peterson SL, Husnain M, Pollack T, et al. Neoadjuvant Nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX. *Anticancer Res*. 2018;38(7):4035-4039. doi:10.21873/anticancer.12692

Philip PA, Lacy J, Portales F, et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. *Lancet Gastroenterol Hepatol*. 2020;5(3):285-294. doi:10.1016/S2468-1253(19)30327-9

Pointet AL, Tougeron D, Pernet S, et al. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study. *Clin Res Hepatol Gastroenterol*. 2020;44(3):295-301. doi:10.1016/j.clinre.2019.08.009

Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial [published correction appears in JAMA. 2008 Apr 23/30;299(16):1902]. *JAMA*. 2008;299(9):1019-1026. doi:10.1001/jama.299.9.1019

Reilly E, Lee J, Zalupski M, et al. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients with Pancreas Adenocarcinoma and Germline BRCA/ PALB@ Mutation. *JCO*. 2020; 38(13):1378-88.

Sohal, Kennedy, Cinar, et al. Metastatic Pancreatic Cancer: ASCO Guideline Update. *J Clin Oncol*.2020;38(27):3217-30. DOI: 10.1200/JCO.20.01364

Springfeld C, Jäger D, Büchler MW, et al. Chemotherapy for pancreatic cancer. *Presse Med*. 2019;48(3 Pt 2):e159-e174. doi:10.1016/j.lpm.2019.02.025

Springfeld C, Jäger D, Büchler MW, et al. Chemotherapy for pancreatic cancer. *Presse Med*. 2019;48(3 Pt 2):e159-e174. doi:10.1016/j.lpm.2019.02.025

Stein SM, James ES, Deng Y, et al. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. *Br J Cancer*. 2016;114(7):737-743. doi:10.1038/bjc.2016.45

Stokes JB, Nolan NJ, Stelow EB, et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. *Ann Surg Oncol*. 2011;18(3):619-627. doi:10.1245/s10434-010-1456-7

Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. *Lancet Oncol*. 2016;17(6):801-810. doi:10.1016/S1470-2045(16)00172-8

SWOG S1505: DOI: 10.1200/JCO.2020.38.15_suppl.4504 *Journal of Clinical Oncology* 38, no. 15_suppl (May 20, 2020) 4504-4504. Published online May 25, 2020.

Tempero M, Plunkett W, Ruiz Van Haperen V, et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. *J Clin Oncol*. 2003;21(18):3402-3408. doi:10.1200/JCO.2003.09.140

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Van Laethem JL, Hammel P, Mornex F, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. *J Clin Oncol*. 2010;28(29):4450-4456. doi:10.1200/JCO.2010.30.3446

Versteijne E, van Eijck CH, Punt CJ, et al. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. *Trials*. 2016;17(1):127. Published 2016 Mar 9. doi:10.1186/s13063-016-1262-z

Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med*. 2013;369(18):1691-1703. doi:10.1056/NEJMoa1304369

Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial [published correction appears in *Lancet*. 2016 Feb 6;387(10018):536]. *Lancet*. 2016;387(10018):545-557. doi:10.1016/S0140-6736(15)00986-1

Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. *Cancer*. 2008 Oct 15;113(8):2046-52. doi:10.1002/cncr.23810. PMID: 18756532.

Yoo C, Hwang JY, Kim JE, et al. A randomized phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. *Br J Cancer*. 2009;101(10):1658-1663. doi:10.1038/sj.bjc.6605374

Zaniboni A, Aitini E, Barni S, et al. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. *Cancer Chemother Pharmacol*. 2012;69(6):1641-1645. doi:10.1007/s00280-012-1875-1

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.